This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Varian Medical Systems Inc. (VAR) is the world’s leading provider of radiotherapy, radiosurgery, proton therapy and brachytherapy for treating cancer and other medical conditions. It is also a premier supplier of X-Ray tubes for medical, scientific, and industrial applications. Notably, Varian Medical is among the top five players when it comes to Oncology Devices market in terms of revenues. The company with all its focus in Oncology business expansion has inflated its Oncology Systems revenue share to 95% in fiscal 2019 from 77% five years back. The main operating segments are Oncology Systems and Proton Therapy. The company also reports an Other segment that includes Ginzton Technology Center (GTC) and Varian Particle Therapy (VPT) businesses.
Varian (VAR) Inks Deal With Google Cloud to Boost Cancer Care
by Zacks Equity Research
Varian (VAR) partners with Google Cloud to help in the fight against cancer through the development of an advanced AI based diagnostic platform.
Varian Medical (VAR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.
Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPME
Why You Should Retain Varian (VAR) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on the Varian (VAR) stock, courtesy of its solid prospects.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
Varian (VAR) Q1 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
Varian's (VAR) receipt of 13 Ethos orders in fiscal Q1 raises investors' optimism on the stock.
Varian Medical Systems, Inc. (VAR) Beats Q1 Earnings Estimates
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) delivered earnings and revenue surprises of 9.62% and -8.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Varian (VAR) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Varian's (VAR) fiscal first-quarter earnings are likely to reflect strength in Halcyon platform.
Varian (VAR) Inks Deal With Yonsei Cancer Center in Korea
by Zacks Equity Research
Varian (VAR) will be coordinating with Yonsei Cancer Center on formulating AI solutions, which are proven to upgrade early detection of cancer.
Here's Why You Should Hold onto Varian Medical (VAR) Stock Now
by Zacks Equity Research
Investor confidence is high on Varian Medical (VAR) stock, courtesy of solid prospects.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
3 Best Buys from the Prospering Medical Instruments Industry
by Urmimala Biswas
Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
Varian (VAR) Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
Varian's (VAR) receipt of 10 Ethos orders in Q4 instills optimism
Varian (VAR) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal fourth-quarter performance.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
5 Stocks in S&P 500 ETF That Have Powered Best Q3 Since 2010
by Sweta Killa
The S&P 500 was up 8.5% in the third quarter, representing its best back-to-back quarter since 2009.
Is JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPME
Varian (VAR) Expands Presence With Germany's Ethos Order
by Zacks Equity Research
Varian's (VAR) Ethos therapy is being adopted in Germany, thus expanding the company's geographic footprint.
Varian Expands Access to Advanced Cancer Treatment With Ethos
by Zacks Equity Research
Varian's (VAR) Ethos Therapy used by Goshen Center for Cancer Care marks the expansion access to personalized cancer care.
Varian's Halcyon System to Bring Improved Care to Singapore
by Zacks Equity Research
Varian (VAR) strengthens its partnership Proton Therapy Pte as it brings improved care to Singapore through Halcyon system.
MedTech Lifts S&P 500 Index: 3 Stocks With Upside Potential
by Urmimala Biswas
MedTech stocks play a major role in holding the index up and ending the shortest bear run in the history of S&P 500.
Why Hold Strategy is Apt for Varian Medical (VAR) Stock Now
by Zacks Equity Research
Investor confidence is high in Varian Medical (VAR) stock at the moment.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Varian's (VAR) Proton Solutions unit saw revenue growth in Q3.
Medical Products Stock Earnings on Aug 5: RMD, ABC & More
by Urmimala Biswas
Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products in the second quarter.